Efficacy of adjuvant chemotherapy with S-1 in patients with positive peritoneal cytology (CY1) who underwent R1 surgery.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 84-84
Author(s):  
M. Terashima ◽  
E. Bando ◽  
M. Tokunaga ◽  
Y. Tanizawa ◽  
T. Kawamura ◽  
...  
Keyword(s):  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Lymph Node Dissection ◽  
Survival Benefit ◽  
Residual Tumor ◽  
Peritoneal Cytology ◽  
Node Dissection ◽  
Significant Survival Benefit ◽  
Significant Survival ◽  
Positive Peritoneal Cytology

84 Background: In recent TNM classification, positive peritoneal cytology (CY1) is regarded as M1 disease and classified into stage IV. However, the prognosis of the CY1 patients underwent R1 surgery (microscopic residual tumor) is considered to be relatively better than those underwent R2 surgery (macroscopic residual tumor). Adjuvant chemotherapy with S-1 had demonstrated significant survival benefit in stage II and III gastric cancer in Japan. However, the efficacy of adjuvant S-1 in patients with relatively more advanced stage had not been investigated. Therefore, we investigated the efficacy of adjuvant chemotherapy with S-1 in CY1 patients underwent R1 surgery. Methods: Among the 2,202 patients with gastric cancer treated at our department between September 2002 and July 2009, a total of 105 patients with CY1 and underwent R1 surgery were included in this study. Clinocopathological features and survival were retrospectively analyzed using prospectively registered data base system. Results: There were 64 male and 41 female patients. The median age was 61 years old. Eighty-five patients had T4a or T4b tumor and 96 patients had lymph node metastasis. Seventy-eight patients had undifferentiated type of tumor. In 83 patients, adjuvant chemotherapy with S-1 had been performed. In the uni-variate analysis, only the extent of lymph node dissection (D2) and the adjuvant chemotherapy with S-1 demonstrated significant survival benefit. In multi-variable analysis using Cox proportional hazarded model, N-factor, extent of lymph node dissection (D2 vs D1), and adjuvant chemotherapy with S-1 were selected as independent prognostic factors. The median survival time and 5-year survival rate in patients underwent R1 resection with D2 lymphadenectomy and adjuvant S-1 treatment were 42 months and 46%, respectively. Conclusions: In patients with CY1 and underwent R1 surgery, adjuvant chemotherapy with S-1 demonstrated significant survival benefit. In patients with positive peritoneal cytology without other non-curative factors, D2 lymph node dissection and adjuvant chemotherapy using S-1 is recommended. No significant financial relationships to disclose.

Does Positive Peritoneal Cytology Not Affect the Prognosis for Stage I Uterine Endometrial Cancer?: The Remaining Controversy and Review of the Literature

2014 ◽  
Vol 24 (3) ◽  
pp. 549-555 ◽  
Author(s):  
Takaya Shiozaki ◽  
Tsutomu Tabata ◽  
Tomomi Yamada ◽  
Yuka Yamamoto ◽  
Takaharu Yamawaki ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Lymph Node ◽  
Lymph Node Dissection ◽  
Cox Model ◽  
Stage I ◽  
Small Scale ◽  
Peritoneal Cytology ◽  
Node Dissection ◽  
Free Survival ◽  
Positive Peritoneal Cytology

ObjectiveThe objective of this study was to elucidate factors that affect prognosis in patients with stage I endometrial cancer.MethodsThe study group comprised 265 patients with stage I endometrial cancer treated surgically at either of our facilities between January 1998 and December 2010 (238 patients with negative peritoneal cytology and 27 patients with positive peritoneal cytology). Progression-free survivals were evaluated between the 2 groups, and multivariate analysis was conducted with correlation factors including positive peritoneal cytology, vessel permeation, lymph node dissection, histologic diagnosis, age at diagnosis, adjuvant chemotherapy, and the depth of myometrial invasion.ResultsDisease-free survival was significantly poorer for patients with positive peritoneal cytology than those with negative peritoneal cytology on stage I disease (P = 0.000). The stratified log-rank test with vessel permeation shows the similar results. By univariate Cox model, positive peritoneal cytology, vessel permeation, and systemic lymph node dissection at surgery are significant factors on stage I endometrial cancer.ConclusionsAlthough this is a small-scale preliminary study with adjustment of other factors, positive peritoneal cytology can contribute to the risk of progression-free survival in patients with stage I endometrial cancer.

scholarly journals Docetaxel, cisplatin and 5-fluorouracil adjuvant chemotherapy following three-field lymph node dissection for stage II/III N1, 2 esophageal cancer

2014 ◽  
Vol 2 (5) ◽  
pp. 719-724 ◽  
Author(s):  
TADASUKE HASHIGUCHI ◽  
MOTOMI NASU ◽  
TAKASHI HASHIMOTO ◽  
TETSUJI KUNIYASU ◽  
HIROHUMI INOUE ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Lymph Node Dissection ◽  
Stage Ii ◽  
Node Dissection

Survival benefit of lateral lymph node dissection according to the region of involvement and the number of lateral lymph nodes involved

Surgery Today ◽  
2013 ◽  
Vol 44 (6) ◽  
pp. 1097-1103 ◽  
Author(s):  
Shozo Yokoyama ◽  
Katsunari Takifuji ◽  
Tsukasa Hotta ◽  
Kenji Matsuda ◽  
Takashi Watanabe ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Nodes ◽  
Lymph Node Dissection ◽  
Survival Benefit ◽  
Lateral Lymph Node Dissection ◽  
Node Dissection ◽  
Lateral Lymph Node

Lateral lymph node dissection after neoadjuvant (chemo)radiotherapy may improve oncological outcomes in Western patients with low rectal cancer.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 163-163 ◽  
Author(s):  
Hidde Maarten Kroon ◽  
Songphol Malakorn ◽  
Nagendra N Dudi-Venkata ◽  
Sergei Bedrikovetski ◽  
Jianliang Liu ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Lymph Node Dissection ◽  
Local Recurrence Rate ◽  
Lateral Lymph Node Dissection ◽  
Short Axis ◽  
Node Dissection ◽  
Lateral Lymph Node ◽  
Oncological Outcomes

163 Background: In the West, rectal cancer patients with pre-treatment abnormal lateral lymph nodes (LLN) are commonly treated with neoadjuvant (chemo)radiotherapy (n(C)RT) followed by total mesorectal excision (TME). Few centers perform lateral lymph node dissection (LLND) in addition to this, with the aim of improving oncological outcomes. To date, no comparative data are available in Western patients. Methods: An international multi-center cohort study was conducted comparing six centers from the Netherlands and Australia treating patients with abnormal LLN (≥5mm short-axis) with n(C)RT and TME (LLND- group) versus similarly staged patients from a dedicated cancer center in the USA who underwent a LLND in addition to n(C)RT and TME (LLND+ group). Results: Data were available on 169 patients. LLND+ patients (n = 44) consisted of significantly younger and more female patients with higher ASA-scores and ypN-stages compared to LLND- patients (n = 115). LLND+ patients also had a larger median LLN short-axis and were more likely to receive adjuvant chemotherapy (100 vs. 30%; p < 0.0001). Between groups, the lateral local recurrence rate (LLRR) was 0% for LLND+ vs. 7% for LLND- (p = 0.09) and the local recurrence rate (LRR) was 3% for LLND+ vs. 11% for LLND- (p = 0.13). No significant differences were observed in disease-free survival (DFS, p = 0.94) or overall survival (OS, p = 0.42). Sub-analysis of patients who underwent adjuvant chemotherapy (LLND- patients: n = 35) demonstrated clinically relevant though non-statistically significant trends towards a lower LLRR (0% for LLND+ vs. 6% for LLND-; p = 0.07), LRR (3% for LLND+ vs. 14% for LLND-; p = 0.06), DFS (p = 0.19) and OS (p = 0.17) in favour of the LLND+ group. Conclusions: Lateral lymph node dissection in addition to neoadjuvant (chemo)radiotherapy may improve oncological outcomes in Western patients with low rectal cancer and abnormal lateral lymph nodes.

scholarly journals Survival benefit of lymph node dissection in surgery for colon cancer in elderly patients: A multicenter propensity score-matched study in Japan

2018 ◽  
Vol 11 (4) ◽  
pp. 346-354
Author(s):  
Makoto Takahashi ◽  
Hiroaki Niitsu ◽  
Kazuhiro Sakamoto ◽  
Takao Hinoi ◽  
Minoru Hattori ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Node ◽  
Propensity Score ◽  
Elderly Patients ◽  
Lymph Node Dissection ◽  
Survival Benefit ◽  
Node Dissection ◽  
Matched Study

scholarly journals Does negative retroperitoneal CT in adolescents with paratesticular rhabdomyosarcoma preclude the need of retroperitoneal lymph node dissection?

2011 ◽  
Vol 9 (4) ◽  
pp. 527-529 ◽  
Author(s):  
Eulalio Damazio ◽  
Eliana Caran ◽  
Valdemar Ortiz ◽  
Antonio Macedo Junior
Keyword(s):  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Lymph Node Dissection ◽  
Metastatic Disease ◽  
Disease Patient ◽  
Group Iv ◽  
Retroperitoneal Lymph Node Dissection ◽  
Study Group ◽  
Node Dissection ◽  
Retroperitoneal Lymph Node

ABSTRACT We report on a 16-year-old male with paratesticular rhabdomyosarcoma who underwent retroperitoneal lymph node dissection due to a stage I tumor (normal retroperitoneal computed tomoghaphy). The surgical finding was three enlarged nodes, positive for metastatic disease. Patient was referred to adjuvant chemotherapy. This case suggests that the Intergroup Rhabdomyosarcoma Study Group IV protocol is subject to questions regarding adolescents with paratesticular rhabdomyosarcoma, and that negative retroperitoneal CT does not preclude the need of lymph node dissection.

Sign in / Sign up

Export Citation Format

Share Document